JP2016513471A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513471A5
JP2016513471A5 JP2016502442A JP2016502442A JP2016513471A5 JP 2016513471 A5 JP2016513471 A5 JP 2016513471A5 JP 2016502442 A JP2016502442 A JP 2016502442A JP 2016502442 A JP2016502442 A JP 2016502442A JP 2016513471 A5 JP2016513471 A5 JP 2016513471A5
Authority
JP
Japan
Prior art keywords
codon
nucleic acid
seq
generates
recombinant nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502442A
Other languages
English (en)
Japanese (ja)
Other versions
JP6506249B2 (ja
JP2016513471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/027447 external-priority patent/WO2014152534A1/en
Publication of JP2016513471A publication Critical patent/JP2016513471A/ja
Publication of JP2016513471A5 publication Critical patent/JP2016513471A5/ja
Priority to JP2019063498A priority Critical patent/JP6956965B2/ja
Application granted granted Critical
Publication of JP6506249B2 publication Critical patent/JP6506249B2/ja
Priority to JP2021153882A priority patent/JP7239948B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502442A 2013-03-14 2014-03-14 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法 Expired - Fee Related JP6506249B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019063498A JP6956965B2 (ja) 2013-03-14 2019-03-28 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2021153882A JP7239948B2 (ja) 2013-03-14 2021-09-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781228P 2013-03-14 2013-03-14
US61/781,228 2013-03-14
US201361890500P 2013-10-14 2013-10-14
US61/890,500 2013-10-14
PCT/US2014/027447 WO2014152534A1 (en) 2013-03-14 2014-03-14 Recombinant rsv with silent mutations, vaccines, and methods related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019063498A Division JP6956965B2 (ja) 2013-03-14 2019-03-28 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法

Publications (3)

Publication Number Publication Date
JP2016513471A JP2016513471A (ja) 2016-05-16
JP2016513471A5 true JP2016513471A5 (https=) 2017-04-20
JP6506249B2 JP6506249B2 (ja) 2019-04-24

Family

ID=51581238

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016502442A Expired - Fee Related JP6506249B2 (ja) 2013-03-14 2014-03-14 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2019063498A Active JP6956965B2 (ja) 2013-03-14 2019-03-28 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2021153882A Active JP7239948B2 (ja) 2013-03-14 2021-09-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2023025816A Pending JP2023062157A (ja) 2013-03-14 2023-02-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019063498A Active JP6956965B2 (ja) 2013-03-14 2019-03-28 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2021153882A Active JP7239948B2 (ja) 2013-03-14 2021-09-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
JP2023025816A Pending JP2023062157A (ja) 2013-03-14 2023-02-22 サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法

Country Status (8)

Country Link
US (4) US10232032B2 (https=)
EP (2) EP3798310A1 (https=)
JP (4) JP6506249B2 (https=)
CN (2) CN105189756B (https=)
AU (3) AU2014239583B2 (https=)
ES (1) ES2854673T3 (https=)
PL (1) PL2970981T3 (https=)
WO (1) WO2014152534A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3798310A1 (en) * 2013-03-14 2021-03-31 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
MX2018005462A (es) * 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
CN109311946A (zh) * 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
WO2019162532A1 (en) 2018-02-26 2019-08-29 Stiftung Tierärztliche Hochschule Hannover (Tiho) Improved pneumovirus reverse genetics
MX2021005607A (es) * 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
EP3923983A4 (en) 2019-02-11 2023-02-22 Emory University CHIMERIC RSV AND HMPV F PROTEINS, IMMUNOGENIC COMPOSITIONS AND METHODS OF USE
EP4319880A4 (en) * 2021-04-08 2025-03-19 Codagenix Inc. Method of eliciting an immune response against respiratory syncytial virus
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof
US20240082385A1 (en) * 2022-05-27 2024-03-14 Meissa Vaccines, Inc. Rsv vaccines and methods of administering same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
WO1998002530A1 (en) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US20020018780A1 (en) 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
EP1613345B1 (en) 2003-03-28 2010-05-26 MedImmune, LLC Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
PT1699919T (pt) 2003-12-24 2017-04-03 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Volksgezondheid Welzijn En Sport Um vírus sincicial respiratório com deficiência genómica complementada em trans
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2008133663A2 (en) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
KR101621100B1 (ko) * 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
US9011876B2 (en) 2008-11-05 2015-04-21 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
PL2370099T3 (pl) * 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
EP2729169A1 (en) 2011-07-06 2014-05-14 Nanobio Corporation Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
EP4190895A1 (en) * 2013-02-08 2023-06-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP3798310A1 (en) * 2013-03-14 2021-03-31 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.

Similar Documents

Publication Publication Date Title
JP2016513471A5 (https=)
CN103442731B (zh) 表达系统
ES2839880T3 (es) Vacuna contra el VRS
CN106661091B (zh) 流行性感冒病毒疫苗及其用途
JP2014530010A5 (https=)
US11905314B2 (en) Influenza virus vaccines and uses thereof
JP2010227101A5 (https=)
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
WO2018028635A1 (zh) 一种寨卡病毒人源单克隆抗体及其应用
JP2019506841A5 (https=)
IL278014B1 (en) Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use
JP2017514522A5 (https=)
JP2012115277A5 (https=)
JP2012511545A5 (https=)
JP2014510519A5 (https=)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
JP2019531293A5 (https=)
JP2015524413A5 (https=)
JP2016520534A5 (https=)
KR20220057578A (ko) 인플루엔자 바이러스 백신 및 이의 용도
JP2016518838A5 (https=)
JP2019512004A5 (https=)
JP2023522154A5 (https=)
Kumaria et al. Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children
CN108794624A (zh) 抗h7n9流感病毒的中和性单克隆抗体